Nimacimab - Bird Rock Bio
Alternative Names: JNJ 2463; Namacizumab; RYI-018Latest Information Update: 20 Nov 2025
At a glance
- Originator Bird Rock Bio
- Developer Beacon Biosignals; Bird Rock Bio; Skye Bioscience
- Class Anti-inflammatories; Antifibrotics; Gastrokinetics; Hepatoprotectants; Monoclonal antibodies; Obesity therapies; Urologics
- Mechanism of Action Cannabinoid receptor CB1 antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Obesity
- No development reported Diabetic nephropathies; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
- Discontinued Diabetic gastroparesis